Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT ID: NCT02176213

Last Updated: 2019-06-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2019-05-07

Brief Summary

This study is being done to learn more about the drug, pomalidomide and to gather data on its safety and side effects when used in combination with commercially available cyclophosphamide and dexamethasone. This combination is considered experimental and has not been approved by the FDA.

Pomalidomide is a third generation immunomodulatory (IMiDs) agent, which is a more potent version of thalidomide and lenalidomide drugs that have been approved by the United States Food and Drug Administration [FDA] for the treatment of MM. In February 2013, pomalidomide was also approved by the FDA for patients with MM who have had more than 2 types of therapy.

Pomalidomide is taken orally as capsules, and cyclophosphamide and dexamethasone are also taken orally as tablets in this study. Cyclophosphamide and dexamethasone are commercially available and are often used in combination with other drugs to treat Multiple Myeloma. Preliminary data from both the laboratory and patient studies suggest that this combination of drugs is more effective than pomalidomide and dexamethasone alone. However, the regimen being used in this study, which consists of daily cyclophosphamide, also permits support of low blood counts with either injections or transfusions as needed.

Detailed Description

This is an open label, single center, phase II study of a combination of pomalidomide, daily low dose oral cyclophosphamide, and dexamethasone in patients with relapsed/refractory multiple myeloma. The three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old). Subjects meeting eligibility criteria with ANC < 1000/µL and platelet count < 50,000/µL will start at dose level -1 of both pomalidomide (3 mg daily) and cyclophosphamide (50 mg daily). G-CSF and platelet transfusion support is permitted if needed.

Dose reduction for hematologic toxicity will begin with cyclophosphamide and then subsequently alternate with pomalidomide until a subject cannot tolerate dose level -2 of both agents - in which case subject would come off study. If subject has 2 or more concurrent toxicities that are potentially attributable to both agents (e.g. hematologic toxicity) then dose modification guidelines will be followed with dose reduction being done sequentially with one agent at a time, unless in the opinion of the investigator, both agents required concurrent dose reduction.

Conditions

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pomalidomide, Cyclophosphamide, Dexamethasone

Three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old)

Group Type: EXPERIMENTAL

Pomalidomide

Intervention Type: DRUG

4 mg PO x 21 days

Cyclophosphamide

Intervention Type: DRUG

low dose cyclophosphamide 50 mg PO BID x 21 days

Dexamethasone

Intervention Type: DRUG

dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).

Interventions

Pomalidomide

4 mg PO x 21 days

Intervention Type: DRUG

Cyclophosphamide

low dose cyclophosphamide 50 mg PO BID x 21 days

Intervention Type: DRUG

Dexamethasone

dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).

Intervention Type: DRUG

Other Intervention Names

pomalyst; cytoxan

Eligibility Criteria

Inclusion Criteria

Disease related:

• Patients must have a history of symptomatic multiple myeloma according to the IMWG criteria
• Patients must have received at least two prior lines of therapy and also must be refractory to lenalidomide.
• Patient has relapsed or relapsed/refractory MM.
• Patients must currently have measurable disease, as defined as:

1. Serum M-protein ≥ 0.5 g/dL

2. Urine M-protein ≥ 200 mg/24 hours

3. Serum free light chain assay: involved FLC level ≥ 10 mg/dl provided serum FLC ratio is abnormal

4. If no monoclonal protein is detected, then > 30% monoclonal bone marrow plasma cells

Demographic:

• Male or female adults ≥ 18 years old
• Able to sign informed consent and to comply with the protocol
• Life expectancy > 12 weeks
• ECOG performance status ≤ 2
• All study participants must be registered into the mandatory POMALYST REMS program, and be willing and able to comply with the requirements of the POMALYST REMS program.

Laboratory

• ANC ≥ 1000/µL
• Platelets ≥ 50,000/µL (Patients with plasma cells 50% of bone marrow nucleated cells, and platelets ≥ 30,000/µL will be permitted regardless of the baseline ANC)
• Cr < 3
• AST ≤ 2.5 x ULN
• ALT ≤ 2.5 x ULN
• Serum Bilirubin ≤ 1.5 x ULN (except patients with Gilbert's syndrome who must have a total bilirubin of <3 time ULN)

Other

• Females of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control at least 28 days before taking pomalidomide.

Exclusion Criteria

• Previous treatment with pomalidomide
• Patients who received chemotherapy or radiation therapy to 30% of marrow-bearing bone within ≤ 2 weeks or experimental agent/therapy within 4 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies
• Known hypersensitivity to thalidomide or lenalidomide
• The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugs
• Other concurrent severe and/or uncontrolled medical conditions including abnormal laboratory values that could cause unacceptable safety risks or compromise compliance with the protocol
• Patients for whom prophylactic anticoagulation therapy is not an option unless due to thrombocytopenia
• Patients who received allogenic stem cell transplantation < 12 months prior to entering the study or show evidence of active graft-versus-host disease that requires immunosuppressive therapy
• Patients with existing peripheral neuropathy grade > 2
• Patients with an active malignancy requiring treatment in the next 12 months (except for basal or squamous cell carcinoma, or in situ cancer of the cervix or breast, and asymptomatic prostate cancer)
• Patients with known positivity for HIV or active hepatitis B or C
• Corticosteroid therapies of > 20 mg/day prednisone, > 4 mg/day dexamethasone, > 80 mg/day hydrocortisone, or equivalent. Oral, inhaled, or topical steroids are allowed during study as long as it does not exceed 80 mg/day hydrocortisone.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene Corporation

INDUSTRY

Sponsor Role: collaborator

Ajai Chari

OTHER

Sponsor Role: lead

Responsible Party

Ajai Chari

Assistant Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Ajai Chari, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Countries

United States

Other Identifiers

PO-CL-MM-PI-002404

Identifier Type: -

Identifier Source: secondary_id

GCO 14-0825

Identifier Type: -

Identifier Source: org_study_id